The implementation of vibration treatment during early postmenopausal osteoporosis (1–20 weeks) promotes osteogenic differentiation and suppresses the progression of postmenopausal osteoporosis via the upregulation of estrogen receptor alpha (Erα) and activation of the canonical Wnt pathway (49). The gene discussed is ESR1; the disease is postmenopausal osteoporosis.